Altimmune (ALT) released 24-week Phase 2b data for pemvidutide in metabolic dysfunction-associated steatohepatitis showing it met the primary endpoint of statistically significant MASH resolution, Stifel analyst Annabel Samimy tells investors in a research note. It also showed promising trends in fibrosis improvement, 5.2% weight loss with no plateau, and strong tolerability, the firm says With these results, Pemvi stands out as a potent, fast-acting GLP-1/GCG agonist that could serve as a single-treatment option for both MASH and obesity. Stifel has a Buy rating and $18 price target on Altimmune shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALT:
- Altimmune’s Pemvidutide: Promising Phase 2b Results Reinforce Buy Rating Amid Stock Decline
- Altimmune selloff on MASH data overdone, says H.C. Wainwright
- Altimmune Announces Positive Phase 2b Trial Results
- Altimmune announces results from IMPACT Phase 2b trial of pemvidutide
- Altimmune to announce Topline 24 week results from Phase 2b trial of Pemvidutide